1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs

Five Launches Bring 2021 First-Time Offerings Total To 67

 
• By Mandy Jackson

Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings. 

Finance Watch Public Company
• Source: Alamy

Erasca Inc. and Imago BioSciences, Inc. raised the most money out of the five biopharmaceutical companies that launched initial public offerings during the first half of July, and their stocks were the only two trading in positive territory after their IPOs.

With first-time offerings by Erasca, Imago, TScan Therapeutics, Unicycive Therapeutics, Inc. and TransCode Therapeutics Inc 67 drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.